This site is intended for healthcare professionals
Latest industry news
  • Home
  • /
  • News
  • /
  • 2020
  • /
  • 12
  • /
  • Novartis acquires Cadent Therapeutics and two new ...
News

Novartis acquires Cadent Therapeutics and two new clinical stage neuroscience programs

Read time: 1 mins
Published:21st Dec 2020
Novartis has entered an agreement to acquire Cadent Therapeutics, a Cambridge, Massachusetts based neuroscience company. The acquisition adds two new clinical stage programs to the Novartis neuroscience portfolio, one for schizophrenia and the other for movement disorders. The agreement also includes a buyout of milestones and royalties for MIJ 821, a clinical stage molecule that Novartis licensed exclusively from Cadent in 2015. Novartis is actively developing MIJ 821 for treatment resistant depression.Under the terms of the agreement, Novartis will acquire all of the outstanding capital stock of Cadent, in exchange for an upfront payment and milestone payments. Cadent and Novartis anticipate the transaction will close during the first quarter of 2021.
Type: industry

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.